当前位置： SCI文献检索 > JOURNAL OF VIRAL HEPATITIS期刊下所有文献 > Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.

Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.

Abstract：

:The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22 months. All patients were Caucasian, 84% were infected with genotype 1b, and 24% had a liver transplantation before treatment. The sustained virological response (SVR12) was 86.0% with ITT analysis. SVR12 was similar among patients with Child-Pugh classes A, B and C disease and transplant recipients. From baseline to SVR12, serum ALT level and MELD score were significantly improved (P < 0.001). LDV/SOF treatment was generally well tolerated. Only one patient developed a new diagnosed HCC. Seventeen of the 35 patients, who had a history of previous HCC, developed HCC recurrence during the LDV/SOF treatment or by a median follow-up of 6 months after treatment. HCC recurrence was less commonly observed in patients who received curative treatment for HCC compared with those patients who received noncurative treatment (P = 0.007). In conclusion, LDV/SOF with or without ribavirin is an effective and tolerable treatment in CHC patients with advanced liver disease. Eradication is associated with improvements in liver function and a reduced risk of developing a new occurrence of HCC.

journal_name

J Viral Hepat

journal_title

Journal of viral hepatitis

authors

Idilman R,Demir M,Aladag M,Erol C,Cavus B,Iliaz R,Koklu H,Cakaloglu Y,Sahin M,Ersoz G,Koksal İ,Karasu Z,Ozgenel M,Turan İ,Gunduz F,Ataseven H,Akdogan M,Kiyici M,Koksal AS,Akhan S,Gunsar F,Tabak F,Kaymakoglu S

doi

10.1111/jvh.13075

subject

Has Abstract

pub_date

2019-06-01 00:00:00

pages

666-674

issue

eissn

1352-0504

issn

1365-2893

journal_volume

pub_type

杂志文章

在线工具

Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.